Strategic Investment: FIG Partners with Elitepharm to Transform Nutraceuticals Using AI

Strategic Investment in Nutraceuticals

Freedom International Group (FIG) has recently taken a significant step in the health and wellness sector by making a strategic investment in Elitepharm Laboratoires. This move marks FIG's entry as a major shareholder in Elitepharm, which is recognized as a leading entity in France for crafting customized dietary supplements.

With over $2.5 billion in assets under management, FIG is committed to innovation in healthcare technology and service delivery. The CEO of FIG, Narek Sirakanyan, emphasized this partnership's transformative potential, stating, "Freedom is making a strategic investment in the healthcare sector. France is an optimal location for producing dietary supplements, given its access to high-quality active ingredients and strict regulatory landscape."

The Vision Behind the Investment

This partnership is not just about capital infusion; it is a strategic alignment that aims to enhance the current capabilities of Elitepharm. The company's expertise in research and development complements FIG's technological strengths, especially in AI. The intention is to leverage AI-driven software to refine dietary supplement formulations, ensuring faster and more reliable outcomes from focus groups.

Narek Sirakanyan and Gérard Strauch, President and CEO of Elitepharm, have articulated a shared vision for the company's future. They aim to consolidate their respective strengths to streamline operations and ultimately enhance production capacity. In line with this goal, Elitepharm plans to increase its monthly capsule production from 25 million to an ambitious 50 million per month by 2029.

A Clear Path Forward

The investment will pave the way for several strategic initiatives, including:
1. Infrastructure Enhancement: Elitepharm aims to upgrade existing facilities and acquire new production sites to meet increasing international demand.
2. Value Chain Control: The company plans to invest in organic farms to ensure optimal traceability and quality of ingredients, further strengthening its supply chain.
3. Private Label Expansion: Collaborating with industry experts will facilitate the expansion of Elitepharm's private label offerings, enabling it to stay competitive and on the cutting edge of market trends.

Commitment to Excellence

With the backing of FIG, Elitepharm is set to accelerate its growth journey, marking a pivotal moment in the company's evolution as it seeks to establish itself as a leading player in Europe. Gérard Strauch believes that this investment will not only bolster their market position but also emphasize a commitment to health and well-being across the region.

By integrating their resources and strategies, both FIG and Elitepharm are determined to cultivate a sustainable industrial model that thrives on innovation and quality. Narek Sirakanyan's comment, "The world is ours," reflects the bold aspirations of this newly formed alliance. Together, they aim to redefine the nutraceutical landscape in Europe, merging advanced technology with the art of supplement formulation.

As FIG and Elitepharm embark on this exciting journey, the health and wellness sector can anticipate a new wave of innovative products that are both effective and compliant with the highest quality standards.

Contact Information: For further inquiries, you may reach out to:
Raffaello Porro
Mobile: +393351015456
Email: [email protected]